C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 2005 Feb 10; 113(4):678-82.